ClinicalTrials.gg
TerminatedNCT05551117TamarackUpdated Feb 9, 2026Results posted

A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

A Phase 2 interventional study of vobramitamab duocarmazine 2.0 mg (Arm A) and vobramitamab duocarmazine 2.7 mg (Arm B) in Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer and Androgen-Insensitive Prostatic Cancer, sponsored by MacroGenics. Terminated at 63 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by MacroGenics · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Business reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States — 18 open to participants now, 24 under way, 3 of them phase 3. Prostatic Neoplasms, Castration-Resistant · United States.

Enrollment
11th of 43
192 · median 82
Started
2023
with 5 others
Phase 2
9 of 51
1 open now
Registered
31st of 51
by date
Lead sponsor
4 of 51
MacroGenics

Among the 51 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States, this one is the 11th largest by enrollment of the 43 interventional ones that give a count, is one of 6 that started in 2023, is one of 9 in phase 2, and was the 31st registered.

Prostatic Neoplasms, Castration-Resistant

86 studies on the registry are indexed under Prostatic Neoplasms, Castration-Resistant; 29 are open to participants now.

Browse Prostatic Neoplasms, Castration-Resistant studies →

Open to participants now

18 of the 51 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 26 Prostatic Neoplasms, Castration-Resistant studies recruiting now, 22 (85%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States, or all of them as a file.
02

Study summary

Study CP-MGC018-03 is an open-label, two-part, Phase 2 study. Part 1 of the study will enroll participants with metastatic castration-resistant prostate cancer (mCRPC) previously treated with one prior androgen receptor axis-targeted therapy (ARAT). ARAT includes abiraterone, enzalutamide, or apalutamide.

Participants may have received up to 1 prior docetaxel-containing regimen, but no other chemotherapy agents.

This part of the study will assess the efficacy and tolerability of vobramitamab duocarmazine (MGC018) in two experimental arms (2.0 mg/kg every 4 weeks [Q4W] and 2.7 mg/kg Q4W) . Approximately 100 participants will be randomized 1:1.

Part 2 of the study will enroll participants with locally advanced or metastatic solid tumors. Participants must have progressive following at least 1 prior line of standard chemotherapy for advanced or metastatic disease. Participants will receive vobramitamab duocarmazine at a dose of 2.7 mg/kg every 4 weeks. Up to 200 participants may be enrolled in Part 2.

In both parts, vobramitamab duocarmazine will be administered intravenously (IV) in clinic on Day 1 of each 4-week cycle. Vobramitamab duocarmazine will be administered until criteria for treatment discontinuation are met. Participants will undergo regular testing for signs of disease progression using computed tomography (CT) scans, magnetic resonance imaging (MRI), bone scans, and prostate-specific antigen (PSA) blood tests. Routine examinations and blood tests will be performed and evaluated by the study doctor.

03

Conditions studied

  • Castration-Resistant Prostatic Cancer
  • Androgen-Independent Prostatic Cancer
  • Androgen-Insensitive Prostatic Cancer
  • Androgen-Resistant Prostatic Cancer
  • Hormone Refractory Prostatic Cancer
  • Anal Cancer
  • Anal Neoplasm
  • Carcinoma, Squamous Cell of Head and Neck
  • Head and Neck Squamous Cell Carcinoma
  • Laryngeal Squamous Cell Carcinoma
  • Oral Squamous Cell Carcinoma
  • Malignant Melanoma
  • Melanoma
  • Non-small Cell Lung Cancer
  • Non-small Cell Carcinoma
  • Small-cell Lung Cancer
  • Small Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Part 1 only: confirmed adenocarcinoma of the prostate without evidence of neuroendocrine differentiation, signet cell, or small cell features.
  • Part 2 only: Histologically confirmed SCC or the anus, melanoma, HNSCC, squamous NSCLC, or SCLC.
  • Part 1 only: Received 1 prior ARAT for or non-metastatic, castration-sensitive or castration-resistant prostate cancer. A second ARAT regimen of \<60 days used as bridging to lutetium-177 is permitted. Up to 3 total for mCRPC are permitted..
  • Part 2 only: At least 1 prior line of systemic therapy for unresectable or metastatic disease and no more than 2 prior lines of cytotoxic chemotherapy. Participants with HNSCC or melanoma must have received prior or PD-L1 inhibitor for advanced or metastatic disease.
  • All participants must have ≥ 1 metastatic lesion, according to 1.1 or PCWG3 criteria, that is present on magnetic resonance imaging (MRI), computed tomography (CT), or bone scan obtained ≤ 28 days prior to initiation of study treatment.
  • All participants must have tumor progression, according to disease-specific criteria, following their most recent anti-cancer therapy.
  • All participants must have and available archival or formalin-fixed paraffin-embedded (FFPE) tumor tissue sample for participants with metastasis to internal organs
  • All participants have acceptable physical condition and laboratory values.
  • All participants of must agree to use highly effective methods of .
  • All participants must not be pregnant, planning to be pregnant, or breastfeeding.

Exclusion criteria

Exclusion Criteria:

  • Any underlying medical or psychiatric condition impairing participant's ability to receive, tolerate, or comply with the planned treatment or study procedures.
  • Part 1 only: Received >1 prior taxane-containing regimen for prostate cancer. A second taxane regimen of \<60 days used as bridging for lutetium-177 is permitted.
  • Part 1 only: Received >3 total prior therapies for mCRPC
  • Part 1 only: Participants with known BRCA or ATM mutation (germline or somatic) are not eligible unless they received prior treatment with a PARP inhibitor where available, indicated and tolerated.
  • Another hematologic or solid tumor ≥ stage 1 that completed surgery, last dose of radiotherapy, or last dose of systemic anti-cancer therapy ≤ 2 years from first dose of study treatment. Participants who had curative therapy for non-melanomatous skin cancer or for localized malignancy are eligible.
  • Untreated, symptomatic central nervous system (CNS) .
  • Prior treatment with any B7-H3 targeted agent for cancer,
  • Contradictions to the use of treatment
  • Prior stem cell, tissue, or solid organ transplant.
  • Part 1 only: Use of products that have published anti-prostate cancer activity or are known to decrease PSA.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
192 participants (actual)

Study arms

  • Experimental
    Part 1: MGC018 2.0 mg (Arm A)

    MGC018 2.0 mg/kg every 4 weeks

    Biological: vobramitamab duocarmazine 2.0 mg (Arm A)

  • Experimental
    Part 1: MGC018 2.7 mg (Arm B)

    MGC018 2.7 mg/kg every 4 weeks

    Biological: vobramitamab duocarmazine 2.7 mg (Arm B)

  • Experimental
    Part 2

    MGC018 2.7 mg/kg every 4 weeks

    Biological: vobramitamab duocarmazine

  • Active comparator
    Part 1: Control Arm

    Patients are administered abiraterone or enzalutamide

    Drug: Abiraterone · Drug: Enzalutamide

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1: Six-month Radiographic Progression Free Survival (rPFS) as Determined by the Investigator

    The landmark analysis for 6 month rPFS rate will occur when all participants on Part 1 have been on study for at least 6 months.

    Time frame: Assessed every 8 weeks for six months. Six month data reported.

  2. Part 2: Objective Response Rate (ORR) Per Investigator Assessment of Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 Criteria

    The ORR is defined as the percentage of participants in the response evaluable population who achieve a best overall response of complete response (CR) or partial response (PR), per RECIST version 1.1 criterial CR is defined as disappearance of all target and non-target lesions. PR is defined as at least a 30% decrease from baseline in the sum of diameters of target lesions.

    Time frame: Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months.

Secondary outcomes

  1. Part 1: ORR Per PCWG3 Criteria as Determined by the Investigator

    To qualify as an objective response, CR and PR require confirmation at least 4 weeks after initial observation of complete response (CR) or partial response (PR). CR + PR = ORR

    Time frame: Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months,

  2. Part 1: Median Duration of Response (DoR) Per PCWG3 Criteria as Determined by the Investigator

    The DoR will be calculated as the time from the date of initial tumor response (CR or PR) to the date of first documented PD or death from any cause, whichever occurs first.

    Time frame: Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months.

  3. Part 1: Mean Best Tumor Size Change Over Time

    Time frame: Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months.

  4. Part 1: Prostate-specific Cancer Antigen (PSA) Response Rate Per PCWG3 Criteria

    PSA response is defined as a ≥ 50% decline in PSA from baseline with PSA confirmation ≥ 3 weeks after the first documented reduction in PSA of ≥ 50%.

    Time frame: Every 4 weeks throughout study participation. Average duration 10 months.

  5. Part 1: Time to PSA Progression Per PCWG3 Criteria

    In participants with a decrease in PSA from baseline, PSA progression is defined as a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir value, which is confirmed by a consecutive second value obtained ≥ 3 weeks later. In participants with no decrease in PSA from baseline, PSA progression is defined as a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the baseline value after 12 weeks. Time to PSA progression is defined as the time from the date of randomization to the first PSA progression.

    Time frame: Every 4 weeks throughout study participation. Average duration of participation, 10 months.

  6. Part 1: Duration of PSA Response Per PCWG3 Criteria

    Duration of PSA response is defined as the time from the date of first documented PSA response to the earliest date of PSA progression.

    Time frame: Every 4 weeks throughout study participation. Average duration of participation, 10 months.

  7. Part 1: Best PSA Percent Change

    Time frame: Every 4 weeks throughout study participation. Average duration of participation, 10 months.

  8. Part 1: Time to First Symptomatic Skeletal Event (SSE)

    An SSE is defined as any of the following events: new symptomatic pathological fracture, requirement for radiation therapy to relieve bone pain, spinal cord compression, or tumor-related orthopedic surgical intervention. The time to first SSE is defined as the time from the date of randomization to the first occurrence of SSE.

    Time frame: Every 4 weeks throughout the study. Average duration of participation, 10 months.

  9. Number of Participants With Adverse Event (AEs), Serious AEs (SAEs), and AEs Leading to Study Treatment Discontinuation.

    Time frame: Throughout the study, average duration of participation, 10 months.

  10. Number of Participants Who Develop Anti-drug Antibodies (ADA)

    Participant specimens were evaluated for the presence of ADA beginning a baseline and throughout the study. If at any time during the study, the results show evidence of ADA, they were counted as ADA positive. There was no time-to- event analysis nor by visit analysis of the data.

    Time frame: Every 4 weeks throughout the study, average duration of participation was 10 months.

  11. Part 2: Median DoR Per Investigator Assessment of RECIST 1.1 Criteria

    The DoR will be calculated as the time from the date of initial tumor response (CR or PR) to the date of first documented progressive disease (PD) or death from any cause, whichever occurs first.

    Time frame: Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months.

  12. Part 2: Median Progression Free Survival (PFS) Per Investigator Assessment of RECIST 1.1 Criteria

    PFS is defined as the time from the date of the first dose to the date of first PD per RECIST 1.1 criteria or death from any cause, whichever occurs first.

    Time frame: Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months.

07

Results

Posted Feb 9, 2026

Participant flow

Participant flow — Overall Study
MilestonePart 1: MGC018 2.0 mg (Arm A)Part 1: MGC018 2.7 mg (Arm B)Part 1: Control ArmPart 2
Started919074
Intent-to-treat population919074
Safety population908634
Tumor response evaluable population594934
Prostate-specific antigen (psa) response evaluable population837100
Anti-drug antibody (ada) evaluable population908604
Completed585622
Not completed333452
Withdrew: Death232002
Withdrew: Lost to follow-up1100
Withdrew: Withdrawal by subject91340
Withdrew: Elected to receive vobramitamab duocarmazine after protocol amendment 2.0010

Outcome measures

PrimaryPart 1: Six-month Radiographic Progression Free Survival (rPFS) as Determined by the Investigator

The landmark analysis for 6 month rPFS rate will occur when all participants on Part 1 have been on study for at least 6 months.

Time frame:
Assessed every 8 weeks for six months. Six month data reported.
Reported as:
Number · proportion of participants
Part 1: Six-month Radiographic Progression Free Survival (rPFS) as Determined by the Investigator
proportion of participantsPart 1: MGC018 2.0 mg (Arm A)Part 1: MGC018 2.7 mg (Arm B)Part 1: Control ArmPart 2
Part 1: Six-month Radiographic Progression Free Survival (rPFS) as Determined by the Investigator0.69 (0.57 to 0.78)0.70 (0.46 to 0.79)0.47 (0.021 to NA)—
PrimaryPart 2: Objective Response Rate (ORR) Per Investigator Assessment of Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 Criteria

The ORR is defined as the percentage of participants in the response evaluable population who achieve a best overall response of complete response (CR) or partial response (PR), per RECIST version 1.1 criterial CR is defined as disappearance of all target and non-target lesions. PR is defined as at least a 30% decrease from baseline in the sum of diameters of target lesions.

Time frame:
Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months.
Reported as:
Number · percentage of participants
Part 2: Objective Response Rate (ORR) Per Investigator Assessment of Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 Criteria
percentage of participantsPart 2
Part 2: Objective Response Rate (ORR) Per Investigator Assessment of Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 Criteria0
SecondaryPart 1: ORR Per PCWG3 Criteria as Determined by the Investigator

To qualify as an objective response, CR and PR require confirmation at least 4 weeks after initial observation of complete response (CR) or partial response (PR). CR + PR = ORR

Time frame:
Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months,
Reported as:
Number · percentage of participants
Part 1: ORR Per PCWG3 Criteria as Determined by the Investigator
percentage of participantsPart 1: MGC018 2.0 mg (Arm A)Part 1: MGC018 2.7 mg (Arm B)Part 1: Control ArmPart 2
Part 1: ORR Per PCWG3 Criteria as Determined by the Investigator13.630.60—
SecondaryPart 1: Median Duration of Response (DoR) Per PCWG3 Criteria as Determined by the Investigator

The DoR will be calculated as the time from the date of initial tumor response (CR or PR) to the date of first documented PD or death from any cause, whichever occurs first.

Time frame:
Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months.
Reported as:
Median · months
Part 1: Median Duration of Response (DoR) Per PCWG3 Criteria as Determined by the Investigator
monthsPart 1: MGC018 2.0 mg (Arm A)Part 1: MGC018 2.7 mg (Arm B)Part 1: Control ArmPart 2
Part 1: Median Duration of Response (DoR) Per PCWG3 Criteria as Determined by the Investigator9.4 (3.68 to NA)9.1 (5.78 to 9.92)——
SecondaryPart 1: Mean Best Tumor Size Change Over Time
Time frame:
Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months.
Reported as:
Mean · percent change from baseline
Part 1: Mean Best Tumor Size Change Over Time
percent change from baselinePart 1: MGC018 2.0 mg (Arm A)Part 1: MGC018 2.7 mg (Arm B)Part 1: Control ArmPart 2
Part 1: Mean Best Tumor Size Change Over Time-13.0 ± 59.70-29.0 ± 33.92-7.44 ± 7.16—
SecondaryPart 1: Prostate-specific Cancer Antigen (PSA) Response Rate Per PCWG3 Criteria

PSA response is defined as a ≥ 50% decline in PSA from baseline with PSA confirmation ≥ 3 weeks after the first documented reduction in PSA of ≥ 50%.

Time frame:
Every 4 weeks throughout study participation. Average duration 10 months.
Reported as:
Number · percent
Part 1: Prostate-specific Cancer Antigen (PSA) Response Rate Per PCWG3 Criteria
percentPart 1: MGC018 2.0 mg (Arm A)Part 1: MGC018 2.7 mg (Arm B)Part 1: Control ArmPart 2
Part 1: Prostate-specific Cancer Antigen (PSA) Response Rate Per PCWG3 Criteria45.8 (34.8 to 57.1)38.0 (26.8 to 50.3)——
SecondaryPart 1: Time to PSA Progression Per PCWG3 Criteria

In participants with a decrease in PSA from baseline, PSA progression is defined as a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir value, which is confirmed by a consecutive second value obtained ≥ 3 weeks later. In participants with no decrease in PSA from baseline, PSA progression is defined as a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the baseline value after 12 weeks. Time to PSA progression is defined as the time from the date of randomization to the first PSA progression.

Time frame:
Every 4 weeks throughout study participation. Average duration of participation, 10 months.
Reported as:
Median · months
Part 1: Time to PSA Progression Per PCWG3 Criteria
monthsPart 1: MGC018 2.0 mg (Arm A)Part 1: MGC018 2.7 mg (Arm B)Part 1: Control ArmPart 2
Part 1: Time to PSA Progression Per PCWG3 Criteria5.9 (4.63 to 6.97)6.9 (4.83 to NA)4.6 (NA to NA)—
SecondaryPart 1: Duration of PSA Response Per PCWG3 Criteria

Duration of PSA response is defined as the time from the date of first documented PSA response to the earliest date of PSA progression.

Time frame:
Every 4 weeks throughout study participation. Average duration of participation, 10 months.
Reported as:
Median · months
Part 1: Duration of PSA Response Per PCWG3 Criteria
monthsPart 1: MGC018 2.0 mg (Arm A)Part 1: MGC018 2.7 mg (Arm B)Part 1: Control ArmPart 2
Part 1: Duration of PSA Response Per PCWG3 Criteria6.1 (4.63 to NA)NA (5.13 to NA)——
SecondaryPart 1: Best PSA Percent Change
Time frame:
Every 4 weeks throughout study participation. Average duration of participation, 10 months.
Reported as:
Mean · percent change from baseline
Part 1: Best PSA Percent Change
percent change from baselinePart 1: MGC018 2.0 mg (Arm A)Part 1: MGC018 2.7 mg (Arm B)Part 1: Control ArmPart 2
Part 1: Best PSA Percent Change-28.7 ± 67.05-33.1 ± 70.89——
SecondaryPart 1: Time to First Symptomatic Skeletal Event (SSE)

An SSE is defined as any of the following events: new symptomatic pathological fracture, requirement for radiation therapy to relieve bone pain, spinal cord compression, or tumor-related orthopedic surgical intervention. The time to first SSE is defined as the time from the date of randomization to the first occurrence of SSE.

Time frame:
Every 4 weeks throughout the study. Average duration of participation, 10 months.
Reported as:
Mean · days
Part 1: Time to First Symptomatic Skeletal Event (SSE)
daysPart 1: MGC018 2.0 mg (Arm A)Part 1: MGC018 2.7 mg (Arm B)Part 1: Control ArmPart 2
Part 1: Time to First Symptomatic Skeletal Event (SSE)3.71 ± 1.9842.80 ± 2.142——
SecondaryNumber of Participants With Adverse Event (AEs), Serious AEs (SAEs), and AEs Leading to Study Treatment Discontinuation.
Time frame:
Throughout the study, average duration of participation, 10 months.
Reported as:
Count of participants · Participants
Number of Participants With Adverse Event (AEs), Serious AEs (SAEs), and AEs Leading to Study Treatment Discontinuation.
ParticipantsPart 1: MGC018 2.0 mg (Arm A)Part 1: MGC018 2.7 mg (Arm B)Part 1: Control ArmPart 2
Any Adverse Event898634
Serious Adverse Events364412
Adverse Events Leading to Discontinuation284102
SecondaryNumber of Participants Who Develop Anti-drug Antibodies (ADA)

Participant specimens were evaluated for the presence of ADA beginning a baseline and throughout the study. If at any time during the study, the results show evidence of ADA, they were counted as ADA positive. There was no time-to- event analysis nor by visit analysis of the data.

Time frame:
Every 4 weeks throughout the study, average duration of participation was 10 months.
Reported as:
Number · participants
Number of Participants Who Develop Anti-drug Antibodies (ADA)
participantsPart 1: MGC018 2.0 mg (Arm A)Part 1: MGC018 2.7 mg (Arm B)Part 1: Control ArmPart 2
Positive ADA at baseline00—0
Positive ADA at any time after dosing.2216—0
SecondaryPart 2: Median DoR Per Investigator Assessment of RECIST 1.1 Criteria

The DoR will be calculated as the time from the date of initial tumor response (CR or PR) to the date of first documented progressive disease (PD) or death from any cause, whichever occurs first.

Time frame:
Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months.

No measurements were reported for this outcome.

SecondaryPart 2: Median Progression Free Survival (PFS) Per Investigator Assessment of RECIST 1.1 Criteria

PFS is defined as the time from the date of the first dose to the date of first PD per RECIST 1.1 criteria or death from any cause, whichever occurs first.

Time frame:
Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months.
Reported as:
Median · months
Part 2: Median Progression Free Survival (PFS) Per Investigator Assessment of RECIST 1.1 Criteria
monthsPart 2
Part 2: Median Progression Free Survival (PFS) Per Investigator Assessment of RECIST 1.1 CriteriaNA (NA to NA)

Adverse events

Collected over Adverse events were collected for each participant from the time of first dose through 28 days after the last dose of study treatment or until the start of another anti-cancer treatment, up to average duration of participation, 10 months months. All-cause mortality was assessed from the time of first dose until death, or participant withdrawal of consent, or the end of the study, whichever was earlier, up to average duration of participation, 10 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: MGC018 2.0 mg (Arm A)25/90 (27.8%)36/90 (40%)89/90 (98.9%)
Part 1: MGC018 2.7 mg (Arm B)21/86 (24.4%)44/86 (51.2%)86/86 (100%)
Part 1: Control Arm1/3 (33.3%)1/3 (33.3%)3/3 (100%)
Part 22/4 (50%)2/4 (50%)4/4 (100%)
Most frequent serious events
Showing 10 of 83
Most frequent serious events
EventPart 1: MGC018 2.0 mg (Arm A)Part 1: MGC018 2.7 mg (Arm B)Part 1: Control ArmPart 2
ConstipationGastrointestinal disorders0/900/861/30/4
Acute kidney injuryRenal and urinary disorders0/900/861/31/4
Urinary retentionRenal and urinary disorders0/900/861/30/4
Abdominal painGastrointestinal disorders0/901/860/31/4
AscitesGastrointestinal disorders0/900/860/31/4
NauseaGastrointestinal disorders0/900/860/31/4
VomitingGastrointestinal disorders0/900/860/31/4
FatigueGeneral disorders0/900/860/31/4
Decreased appetiteMetabolism and nutrition disorders0/900/860/31/4
HyponatraemiaMetabolism and nutrition disorders0/900/860/31/4
Most frequent other events
Showing 10 of 49
Most frequent other events
EventPart 1: MGC018 2.0 mg (Arm A)Part 1: MGC018 2.7 mg (Arm B)Part 1: Control ArmPart 2
FatigueGeneral disorders25/9020/862/32/4
Back painMusculoskeletal and connective tissue disorders8/9010/862/31/4
AstheniaGeneral disorders47/9052/860/30/4
ConstipationGastrointestinal disorders22/9020/860/32/4
HeadacheNervous system disorders12/9016/860/32/4
Oedema peripheralGeneral disorders33/9035/860/31/4
Decreased appetiteMetabolism and nutrition disorders33/9035/860/30/4
NauseaGastrointestinal disorders32/9026/861/30/4
Pleural effusionRespiratory, thoracic and mediastinal disorders25/9029/860/30/4
AnaemiaBlood and lymphatic system disorders19/9023/861/31/4

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part 1: MGC018 2.0 mg (Arm A)Part 1: MGC018 2.7 mg (Arm B)Part 1: Control ArmPart 2Total
Mean70.3 ± 9.0369.1 ± 8.9465.7 ± 10.4751.8 ± 12.9769.2 ± 9.45
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Part 1: MGC018 2.0 mg (Arm A)Part 1: MGC018 2.7 mg (Arm B)Part 1: Control ArmPart 2Total
Female00033
Male909071188
Undifferentiated10001
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: MGC018 2.0 mg (Arm A)Part 1: MGC018 2.7 mg (Arm B)Part 1: Control ArmPart 2Total
Hispanic or Latino1180019
Not Hispanic or Latino475064107
Unknown or Not Reported33321066
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: MGC018 2.0 mg (Arm A)Part 1: MGC018 2.7 mg (Arm B)Part 1: Control ArmPart 2Total
American Indian or Alaska Native00000
Asian33118
Native Hawaiian or Other Pacific Islander00000
Black or African American24006
White494662103
More than one race10001
Unknown or Not Reported36370174
Region of Enrollment
Region of Enrollment(participants)Part 1: MGC018 2.0 mg (Arm A)Part 1: MGC018 2.7 mg (Arm B)Part 1: Control ArmPart 2Total
South Korea23106
Belgium45009
United States11101426
Poland880016
Italy34007
United Kingdom644014
Australia41106
France35350070
Spain18200038
08

Study locations

63 sites
  • Compassionate Cancer Care Medical Group
    Fountain Valley, California 92708, United States
  • University of California Los Angeles (UCLA) Community Cancer Care
    Los Angeles, California 90095, United States
  • The University of Florida Health System - UF Health Urology - Jacksonville
    Jacksonville, Florida 32209, United States
  • Mid Florida Hematology and Oncology Center
    Orange City, Florida 32763, United States
  • Pontchartrain Cancer Center
    Covington, Louisiana 70433, United States
  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Baltimore, Maryland 21231, United States
  • Barbara Ann Karmanos Cancer Institute - Hudson-Webber Cancer Research Center
    Detroit, Michigan 48201, United States
  • Masonic Cancer Center, University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
  • VA Portland Health Care Services
    Portland, Oregon 97239, United States
  • Carolina Urologic Research Center
    Myrtle Beach, South Carolina 29572, United States
  • University of Virginia Comprehensive Cancer Center
    Charlottesville, Virginia 22908, United States
  • Virginia Cancer Specalists
    Fairfax, Virginia 22031, United States
  • Fred Hutchinson Cancer Center
    Seattle, Washington 98109, United States
  • Ramsay Health Care - Westmead Private Hospital
    Westmead, New South Wales 2145, Australia
  • The University of Queensland (UQ) - Princess Alexandra Hospital (PAH)
    Woolloongabba, Queensland 4102, Australia
  • Cabrini Health- Malvern
    Malvern, Victoria 3144, Australia
  • Peter MacCallum Cancer Centre
    Melbourne, Victoria 3000, Australia
  • Cliniques Universitaires Saint-Luc
    Woluwe-Saint-Lambert, Brussles 1200, Belgium
  • (Grand Hopital de Charleroi) GHDC
    Charleroi, Hainaut 6000, Belgium
  • Centre Hospitalier de Ardenne - Libramont - Clinique du Sein
    Libramont, Luxembourg 6800, Belgium
  • Centre Hospitalier Universitaire (CHU) - Universite Catholique de Louvain (UCL) - Namur - Site Godinne (Cliniques Universitaires UCL de Mont-Godinne)
    Godinne, Namur 5300, Belgium
  • Algemeen Ziekenhuis Maria Middelares
    Ghent, 9000, Belgium
  • Centre Antoine-Lacassagne
    Nice, AM 06189, France
  • Institut de Cancerologie Strasbourg Europe (ICANS)
    Strasbourg, Bas Rhin 67200, France
  • Institut Bergonié
    Bordeaux, Gironde 33076, France
  • Institut régional du Cancer de Montpellier - ICM Val d'Aurelle
    Montpellier, Herault 34298, France
  • Centre Hospitalier Privé Saint-Grégoire
    Saint-Grégoire, Ille Et Vilaine 35760, France
  • Clinique Victor Hugo
    Le Mans, Sarthe 72000, France
  • Gustave Roussy
    Villejuif, Val De Marne 94800, France
  • CHRU Brest
    Brest, 29200, France
  • Institut Mutualiste Montsouris
    Paris, 75014, France
  • Hôpital d'Instruction des Armées Bégin
    Saint-Mandé, Île-de-France Region 94160, France
  • Hopital Foch
    Suresnes, Île-de-France Region 92150, France
  • AOU San Luigi Gonzaga Oncology Department
    Orbassano, TO 10049, Italy
  • Ospedale dell'Angelo
    Mestre, Venice 30174, Italy
  • Radiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence
    Florence, 50134, Italy
  • Istituto Oncologico Veneto
    Padova, 35128, Italy
  • Azienda Provinciale per i Servizi Sanitari - Presidio Ospedaliero S. Chiara
    Trento, 38122, Italy
  • Szpital im. Fryderyka Chopina
    Otwock, Masovian Voivodeship 05-400, Poland
  • Magodent Szpital Elblaska
    Warsaw, Masovian Voivodeship 01-748, Poland
  • Medical Concierge Centrum Medyczne
    Warsaw, Masovian Voivodeship 02-798, Poland
  • Grochowski Hospital
    Warsaw, Masovian Voivodeship 04-073, Poland
  • Szpital Wojewodzki im. Mikolaja Kopernika
    Koszalin, West Pomeranian Voivodeship 75-581, Poland
  • Przychodnia Lekarska "KOMED"
    Konin, WLKP 62-500, Poland
  • Kyungpook National University Chilgok Hospital
    Bugok, Daegu 41404, South Korea
  • National Cancer Center
    Goyang-si, Gyeonggi-do 10408, South Korea
  • Chonnam National University Hospital
    Gwangju, 61469, South Korea
  • Seoul National University Hopital
    Seoul, 03080, South Korea
  • Yonsei University Health System, Severance Hospital
    Seoul, 03722, South Korea
  • Samsung Meical Cemter
    Seoul, 06351, South Korea
  • Ewha Womans University Mokdong Hospital
    Seoul, 07985, South Korea
  • Asan Medical Center
    Seoul, 5505, South Korea
  • Hospital Universitari Parc Taulí
    Sabadell, Barcelona 08208, Spain
  • Hospital Universitario Virgen del Rocio
    Seville, Seville 41013, Spain
  • Hospital Del Mar
    Barcelona, 08003, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital de la Santa Creu I Sant Pau
    Barcelona, 08036, Spain
  • Institut Catala d'Oncologia Hospitalet
    Barcelona, 08036, Spain
  • Hospital Universitario Lucus Augusti
    Lugo, 27002, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • The Royal Marsden NHS Trust
    Sutton, Surrey SM2 5PT, United Kingdom
  • Oxford University Hospitals NHS- Churchill Hospital
    Oxford, OX3 7LE, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Jul 2024, 12 months.

Results were first posted in Feb 2026, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2022
First posted
Sep 22, 2022
StartActual
Jun 13, 2023
Primary completionActual
Jul 4, 2024
CompletionActual
Jan 23, 2025
Results first posted
Feb 9, 2026
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05551117
Lead sponsor
MacroGenics
Responsible party
Sponsor
First posted
Sep 22, 2022
Start date
Jun 13, 2023
Primary completion
Jul 4, 2024
Completion
Jan 23, 2025
Results posted
Feb 9, 2026
Last update
Feb 9, 2026

Study contacts

Liudmila Schafer, M.D.
study director · MacroGenics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vobramitamab duocarmazine

Start the discussion